Comparative observational study between Atorvastatin and Rosuvastatin based on HbA1c levels of patients diagnosed with acute coronary syndrome and heart failure
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20233902Keywords:
ACS, HF, HbA1c, Diabetes Mellitus, StatinsAbstract
Background: Our study aims to compare HbA1c levels in hospitalized acute coronary syndrome and heart failure patients treated with atorvastatin versus rosuvastatin
Methods: This is a retrospective, prospective observational study in which the study population includes ACS and HF Hospitalized patients, the study subjects are divided based on patients prescribed with Atorvastatin and Rosuvastatin based on the medication chart, and those patients' previous history of statin use is collected from history chart, patient case notes, doctors notes, laboratory data is collected and documented in data collection form, lab data includes HbA1c, finally compared Atorvastatin and Rosuvastatin using excel and JASP descriptive analysis.
Results: Overall, we collected data for 132 cases, of which 55% are males and 45% females, 59.10% are above 61 years of age, 39.39% are diagnosed with ACS and 23.48% are diagnosed with HF, among 67 patients who are using Atorvastatin, there was a significant mean decrease in HbA1c% from 8.359% to 7.901%, and among 65 Rosuvastatin users there was an increase in mean HbA1c% from 8.386% to 8.389%. Additionally for non-diabetic individuals, there was an increase in Hba1c% from 6.339% to 6.387%.
Conclusions: We concluded that Atorvastatin is a more effective statin than Rosuvastatin which will reduce the risk of new-onset Diabetes Mellitus in non- diabetic individuals and reduce the risk of increasing complications of diabetes mellitus in patients who are Diabetic.
References
Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmocol. 2005;19(1):117-25.
Widyahening IS, Wangge G, van der Graaf Y, van der Heijden GJ. Adapting clinical guidelines in low-resources countries: a study on the guideline on the management and prevention of type 2 diabetes mellitus in Indonesia. J Eval Clin Pract. 2017;23(1):121-7.
Mach FO, Ray KK, Wiklund O, Corsini A, Catapano AL, Bruckert E, et al. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal, and hepatic function, hemorrhagic stroke, and cataract. Eur Heart J. 2018;39(27):2526-39.
Lin S, Baumann K, Zhou C, Zhou W, Cuellar AE, Xue H. Trends in Use and Expenditures for Brand-name Statins After Introduction of Generic Statins in the US. JAMA. 2021;4(11):e213.
Mitchell AP, Simpson RJ. Statin cost-effectiveness in primary prevention: A systematic review of the recent cost-effectiveness literature in the United States. BMC Res Notes. 2012;5:373.
Maron DJ, Sergio F, Linton MF. Current Perspectives on Statins. Aha J. 2000;101:207-13.
Van Staa TP, Carr DF, O'Meara H, McCann G, Pirmohamed M. Predictors and outcomes of increases in creatine phosphokinase concentrations or rhabdomyolysis risk during statin treatment. Br J Clin Pharmacol. 2014;78(3):649-59.
Nathan DM, Lachin JM, Balasubramanyam A, Burch HB, Buse JB, Nicole M. Butera, Glycemia Reduction in Type 2 Diabetes -Glycemic Outcomes. N Engl J Med. 2022;387:1063-74.
Schwartz SS. Changing the Face of Diabetes. Int J Diabetes Clin Res. 2022;9:157.
Bajaj T, Giwa AO. Rosuvastatin. Treasure Island (FL): StatPearls Publishing; 2022.
George H, Dar-Esaif Y, Bishara H. The impact of corticosteroid treatment on hemoglobin A1C levels among patients with type-2 diabetes with chronic obstructive pulmonary disease exacerbation. Resp Med. (2014);108:1641-6.
Unnikrishnan R, Anjana RM, Mohan V. Drugs affecting HbA1c levels. Indian J Endocrinol Metab. 2012;16(4):528-31.
Ahmed A, John M, Sudarshan R. Rosuvastatin and Atorvastatin: comparative effects on Glucose Metabolism in non-diabetic patients with Dyslipidaemia. Endocrinol Diab 2012;5:13-30.
Kon KK, Quon MJ. Atorvastatin Causes Insulin Resistance and Increases Ambient Glycemia in Hypercholesterolemic Patients. Am Coll Cardiol. 2010;55(12):1209-16.
Son WD, Teng CL. Do statins adversely affect the Hba1c of diabetic patients? Malays Fam Physician. 2017;12(1):40.
James HO, DiNicolantonio JJ, Lavie CJ, Bell SH. The Influence of Statins on Glucose Tolerance and Incipient Diabetes. US Endocrinol. 2014;10(1):68-74.
Shih-Hao H, Peng-Ju H, Jhong-You L. Hemoglobin A1c Levels Associated with Age and Gender in Taiwanese Adults without Prior Diagnosis with Diabetes. Int J Environ Res. 2021;18:3390.
